Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study

Louis E. Schroder; Danika Lew; Robert C. Flanigan; Mario A. Eisenberger; Thomas E. Seay; Neel Hammond; Burton M. Needles; E. David Crawford

doi:10.1016/S1078-1439(00)00126-5

Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study

Louis E. Schroder, Danika Lew, Robert C. Flanigan, Mario A. Eisenberger, Thomas E. Seay, Neel Hammond, Burton M. Needles, E. David Crawford

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.

Original language	English (US)
Pages (from-to)	145-148
Number of pages	4
Journal	Urologic oncology
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/S1078-1439(00)00126-5
State	Published - 2001
Externally published	Yes

Keywords

Renal carcinoma
Suramin

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/S1078-1439(00)00126-5

Cite this

@article{f4631d3678654af5ad5328194d12ff92,

title = "Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study",

abstract = "Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.",

keywords = "Renal carcinoma, Suramin",

author = "Schroder, {Louis E.} and Danika Lew and Flanigan, {Robert C.} and Eisenberger, {Mario A.} and Seay, {Thomas E.} and Neel Hammond and Needles, {Burton M.} and Crawford, {E. David}",

note = "Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA45450, CA52386, CA35128, CA58416, CA35176, CA68183, CA46441, CA35178, CA22433, CA58415, CA35431, CA76462. ",

year = "2001",

doi = "10.1016/S1078-1439(00)00126-5",

language = "English (US)",

volume = "6",

pages = "145--148",

journal = "Urologic oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Phase II evaluation of suramin in advanced renal cell carcinoma

T2 - A Southwest Oncology Group study

AU - Schroder, Louis E.

AU - Lew, Danika

AU - Flanigan, Robert C.

AU - Eisenberger, Mario A.

AU - Seay, Thomas E.

AU - Hammond, Neel

AU - Needles, Burton M.

AU - Crawford, E. David

N1 - Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA45450, CA52386, CA35128, CA58416, CA35176, CA68183, CA46441, CA35178, CA22433, CA58415, CA35431, CA76462.

PY - 2001

Y1 - 2001

N2 - Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.

AB - Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.

KW - Renal carcinoma

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0034978393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034978393&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(00)00126-5

DO - 10.1016/S1078-1439(00)00126-5

M3 - Article

AN - SCOPUS:0034978393

SN - 1078-1439

VL - 6

SP - 145

EP - 148

JO - Urologic oncology

JF - Urologic oncology

IS - 4

ER -

Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this